We are live on ! Find out more
CCM

Copernicus Capital Management Portfolio holdings

AUM $8.26M
1-Year Est. Return 37.91%
This Fund
S&P 500
This Quarter Est. Return
-4.74%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$82.6M
AUM Growth
+$6.37M
Cap. Flow
+$10.3M
Cap. Flow %
12.44%
Top 10 Hldgs %
89%
Holding
21
New
6
Increased
3
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$8.68M
2
MCK icon
McKesson
MCK
+$7.47M
3
BIIB icon
Biogen
BIIB
+$5.46M
4
CI icon
Cigna
CI
+$2.86M
5
CNC icon
Centene
CNC
+$2.85M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$6.81M
2
IQV icon
IQVIA
IQV
+$6.27M
3
SIEN
Sientra, Inc.
SIEN
+$3.44M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$1.96M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.79M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
1
Vertex Pharmaceuticals
VRTX
$120B
$12.5M 15.1%
52,453
-5,362
-9% -$1.23M
BMY icon
2
Bristol-Myers Squibb
BMY
$126B
$9.87M 11.94%
176,997
+44,165
+33% +$2.7M
CI icon
3
Cigna
CI
$75.7B
$9.7M 11.74%
54,748
+14,748
+37% +$2.86M
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$11.4B
$8.72M 10.55%
103,179
-20,779
-17% -$1.79M
CVS icon
5
CVS Health
CVS
$136B
$7.71M 9.33%
+130,000
New +$8.68M
MCK icon
6
McKesson
MCK
$96.5B
$6.9M 8.35%
+51,000
New +$7.47M
BIIB icon
7
Biogen
BIIB
$29.6B
$5.7M 6.89%
+18,000
New +$5.46M
TMO icon
8
Thermo Fisher Scientific
TMO
$213B
$5.36M 6.48%
18,896
+8,937
+90% +$2.82M
FATE icon
9
Fate Therapeutics
FATE
$294M
$3.58M 4.33%
160,959
-1,018
-0.6% -$25.7K
ZTS icon
10
Zoetis
ZTS
$31.3B
$3.54M 4.29%
30,125
-190
-0.6% -$25K
CNC icon
11
Centene
CNC
$31.5B
$2.79M 3.38%
+47,000
New +$2.85M
TNDM icon
12
Tandem Diabetes Care
TNDM
$1.16B
$2.75M 3.32%
42,685
-7,315
-15% -$513K
ARNA
13
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.89M 2.29%
+45,000
New +$2.06M
SWAV
14
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$1.66M 2.01%
+50,000
New +$1.99M
ABBV icon
15
AbbVie
ABBV
$454B
– –
-76,957
Closed -$6.81M
ASND icon
16
Ascendis Pharma A/S
ASND
$16.6B
– –
-12,000
Closed -$1.67M
HUM icon
17
Humana
HUM
$47.4B
– –
-3,942
Closed -$1.45M
ILMN icon
18
Illumina
ILMN
$29.8B
– –
-4,430
Closed -$1.43M
IQV icon
19
IQVIA
IQV
$34.6B
– –
-40,585
Closed -$6.27M
KRTX
20
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-26,000
Closed -$1.96M
SIEN
21
DELISTED
Sientra, Inc.
SIEN
– –
-38,481
Closed -$3.44M

Similar funds

AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
YEPV
Yorktown Energy Partners VI New York $6.21M AUM 74.4% 1-Year Est. Return
LC
Lunia Capital Dallas, Texas $4.49M AUM 42.82% 1-Year Est. Return
MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Copernicus Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Copernicus Capital Management held 21 positions worth $82.6M, up 8.3% from $76.3M the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Copernicus Capital Management deployed $10.3M of net new capital in Q1 2020, opening 6 new positions and adding to 3 existing holdings. Its largest new stake was CVS Health: 130,000 shares worth $7.71M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $1.79M trimmed.

  • Copernicus Capital Management's largest Q1 2020 buy was CVS Health: 130,000 shares worth $7.71M.
  • Copernicus Capital Management added most to Cigna in Q1 2020, an estimated $2.86M increase.
  • Copernicus Capital Management's biggest Q1 2020 reduction was BioMarin Pharmaceuticals, cutting an estimated $1.79M.
  • Copernicus Capital Management fully exited AbbVie in Q1 2020, selling an estimated $6.81M.
  • Copernicus Capital Management's ten largest holdings make up 89% of its $82.6M portfolio in Q1 2020.
  • Copernicus Capital Management opened 6 new positions and closed 7 in Q1 2020.
  • Copernicus Capital Management's portfolio value rose 8.3% quarter-over-quarter to $82.6M.

Based on Copernicus Capital Management's 13F filing for Q1 2020, filed 14 May 2020.